Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Search Results

Your search for the word "dupilumab" returned 19 results
1 - 15 of 19 Content Items

How does dupilumab perform in the long term?

November 1, 2017
Physician Editor Abby Van Voorhees, MD, talks with Andrew Blauvelt, MD, MBA, about his recent Lancet article. ... article, " Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant... was this study different from the phase 3 trial for dupilumab that had only a placebo arm? Why were

Does dupilumab pass the test for atopic dermatitis?

January 1, 2017
Physician Editor Abby Van Voorhees, MD, talks with Eric L. Simpson, MD, MCR about his recent New England Journal of Medicine article. ... Journal of Medicine article, " ... Two Phase 3 Trials of Dupilumab versus Placebo in Atopic... negative effects on barrier function creating a vicious cycle. ... Dr. Van Voorhees: Dupilumab

September 26

September 27, 2018
users Dupilumab improves adolescent atopic dermatitis, quality of life Drug prices spike after...: 2018 MIPS Reporting Module AADA web: MACRA Resource Center Dupilumab improves adolescent atopic

Filling the medicine cabinet

August 1, 2018
Dupilumab and crisaborole could be just the start of an atopic dermatitis treatment revolution. ... of stinging and burning at the application site, where does dupilumab stand in the pediatric space...Back to current issue Menu ... Dupilumab and crisaborole have changed atopic dermatitis treatment

2 FDA-approved medications increase treatment options for eczema

March 15, 2018
Two FDA-approved medications are giving people who have eczema more treatment options. ... for this medication is dupilumab (do-pill-you-mab). It’s considered a breakthrough treatment..., another common skin disease. ... We still don’t know whether dupilumab can be safely taken

Playing the angles

December 1, 2016
New treatments target potential pathways for atopic dermatitis. ... disease control." ... Dupilumab – Interleukin (IL) 4/IL-13 Dupilumab is often the first biologic that comes to mind for atopic dermatitis. "Dupilumab really represents a potential paradigm shift

What's hot?

June 1, 2017
Members of DW's Editorial Advisory Workgroup share exciting news from across the specialty. ... ANP-BC ... Well, it’s finally here! ... On March 28, the FDA approved dupilumab (Dupixent, Regeneron... of dupilumab were established in three placebo-controlled clinical trials with a total of 2,119 adult

November 28

December 3, 2018
to the supplemental Biologics License Application (sBLA) of dupilumab (Dupixent) to treat moderate... by phase 3 trial data indicating that dupilumab significantly improves symptoms in adolescents

Giving research a boost

October 1, 2017
Academy President Henry Lim, MD, talks about what needs to be done to give medical research funding a boost. ... dupilumab, and a topical PDE-4 inhibitor, crisaborole. In fact, so far in 2017, the FDA has approved 26 new

September 19

September 18, 2018
on disease improvement to reduce these risks. Learn more about how drugs like dupilumab

Ripe for the picking

September 1, 2015
Experts profile the future of biologic treatments ... is dupilumab." ... Dupilumab — developed by Regeneron Pharmaceuticals and Sanofi — is a monoclonal antibody... was reversed after only four weeks of dupilumab treatment, showing a dose effect molecular and histologic

From bench to bedside

March 1, 2015
Dermatology World looks at new discoveries in dermatology that will influence clinical practice in the future. ... dermatitis, bad eczema, and there’s a drug in development, dupilumab, which will be dramatically effective," Dr. Lebwohl said. ... Phase II trials have shown that dupilumab, which blocks IL-4 and IL-13

A new understanding of itch and eczema

May 1, 2018
Physician editor Kathryn Schwarzenberger, MD, talks with Brian Kim, MD, MTR, about his recent Cell article. ... and IL-13. Well, we now know that drugs like dupilumab, tralokinumab, and lebrikizumab block

What's hot?

October 1, 2016
Members of DW's Editorial Advisory Workgroup share exciting news from across the specialty. ... MSN, ANP-BC While many dermatology providers are anxiously awaiting the approval of dupilumab... versus daily application (BCC: RR 1.03, 95 percent CI 0.74 to 1.43 / SCC: RR 0.88, 95 percent CI

What's hot?

February 1, 2016
Members of DW's Editorial Advisory Workgroup share exciting news from across the specialty. ... are requisite drivers of atopic dermatitis ( ... N Engl J Med 2014; 371:130-139 ). Dupilumab
1 - 15 of 19 Content Items